Ladenburg Thalmann Downgrades Traws Pharma to Neutral

Benzinga Newsdesk www.benzinga.com Negative 92.6%

Neg 92.6% Neu 0% Pos 0%

Ladenburg Thalmann analyst Kevin DeGeeter downgrades Traws Pharma (NASDAQ:TRAW) from Buy to Neutral.

Comments

No comments yet. Be the first!